NASDAQ : ALGS
Aligos Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.8 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 29.97M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 28.72M |
| Enterprise Value | 1.85M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 5.44M |
| Shares Outstanding | 6.24M |
| Shares Change (YoY) | +32.81% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 2.22% |
| Owned by Institutions (%) | 17.79% |
| Float | 3.68M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.91 |
| Forward PS | 4.35 |
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.19 |
| Quick Ratio | 2.05 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -113.59% |
| Return on Assets (ROA) | -49.12% |
| Return on Invested Capital (ROIC) | -68.51% |
| Return on Capital Employed (ROCE) | -207.97% |
| Weighted Average Cost of Capital (WACC) | 15.68% |
| Revenue Per Employee | $384,366 |
| Profits Per Employee | -$926,366 |
| Employee Count | 82 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 3.21M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.43 |
| 52-Week Price Change | -44.24% |
| 50-Day Moving Average | 5.52 |
| 200-Day Moving Average | 6.22 |
| Relative Strength Index (RSI) | 37.46 |
| Average Volume (20 Days) | 32,081 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 707,471 |
| Short Previous Month | 708,744 |
| Short % of Shares Out | 11.33% |
| Short % of Float | 19.22% |
| Short Ratio (days to cover) | 17.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 31.52M |
| Gross Profit | -56.86M |
| Operating Income | -78.99M |
| Pretax Income | -72.75M |
| Net Income | -75.96M |
| EBITDA | -77.92M |
| EBIT | -78.99M |
| Loss Per Share | -$7.31 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 30.38M |
| Total Debt | 3.50M |
| Net Cash | 26.88M |
| Net Cash Per Share | $4.30 |
| Equity (Book Value) | 31.88M |
| Book Value Per Share | 5.11 |
| Working Capital | 33.78M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -94.17M |
| Capital Expenditures | -355,000 |
| Depreciation & Amortization | 1.08M |
| Net Borrowing | -91,000 |
| Free Cash Flow | -94.52M |
| FCF Per Share | -$15.14 |
Margins
| Measure | Value |
|---|
| Gross Margin | -180.40% |
| Operating Margin | -250.63% |
| Pretax Margin | -230.81% |
| Profit Margin | -241.01% |
| EBITDA Margin | -247.21% |
| EBIT Margin | -250.63% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -32.81% |
| Shareholder Yield | -32.81% |
| Earnings Yield | -158.99% |
| FCF Yield | -329.06% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $52.38 |
| Price Target Difference | 1,038.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 187.75% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 19, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -16.05 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |